Losartan half life
Pro Research Analysisby 
Searched over 200M research papers
Losartan Half-Life: Pharmacokinetics and Clinical Implications
Introduction to Losartan Pharmacokinetics
Losartan is a widely used angiotensin II receptor antagonist, primarily prescribed for hypertension and heart failure. Understanding its pharmacokinetics, including its half-life, is crucial for optimizing its therapeutic efficacy and safety.
Losartan Absorption and Metabolism
After oral administration, losartan is rapidly absorbed, reaching peak plasma concentrations within 1 to 2 hours Sica2005Lo1995. However, its oral bioavailability is relatively low at approximately 33%, mainly due to extensive first-pass metabolism Lo1995Nakashima1996. Losartan is metabolized in the liver to its active metabolite, E-3174, which is significantly more potent than the parent compound Sica2005Lo1995.
Half-Life of Losartan and Its Metabolite E-3174
The terminal half-life of losartan itself is relatively short, ranging from 1.5 to 2.5 hours Nakashima1996Ohtawa1993Lo1998. In contrast, the active metabolite E-3174 has a longer half-life, typically between 6 to 9 hours Sica2005Lo1995Lo1998. This extended half-life of E-3174 contributes to the prolonged pharmacological effects of losartan, allowing for once-daily dosing in most therapeutic regimens Sica2005Goldberg1996.
Factors Influencing Losartan Pharmacokinetics
The pharmacokinetics of losartan and E-3174 are generally linear and dose-proportional, with no significant changes observed with repetitive administration Sica2005Ohtawa1993. Additionally, factors such as age, sex, and race do not significantly affect the pharmacokinetics of losartan, and no dosage adjustments are necessary for patients with mild hepatic impairment or varying degrees of renal insufficiency .
Clinical Implications of Losartan's Half-Life
The relatively short half-life of losartan necessitates its conversion to the longer-acting E-3174 to maintain therapeutic efficacy. This conversion is crucial for the drug's sustained antihypertensive and cardioprotective effects Sica2005Lo1995Lo1998. The extended half-life of E-3174 ensures that losartan can be administered once daily, improving patient compliance and convenience Sica2005Goldberg1996.
Conclusion
Losartan's pharmacokinetic profile, characterized by a short half-life of the parent compound and a longer half-life of its active metabolite E-3174, underpins its clinical efficacy in managing hypertension and heart failure. Understanding these pharmacokinetic properties helps in optimizing dosing regimens and enhancing therapeutic outcomes.
Sources and full results
Most relevant research papers on this topic